Vivos Therapeutics reports Q3 revenue growth, regains Nasdaq compliance
Vivos Therapeutics (VVOS) reported Q3 2026 revenue of $6.4M, up 24% from Q2 2026. Operating loss improved 18% YoY to $3.9M. Nine-month revenue rose 23% to $16.7M. Gross margin was 52% in Q3. Net loss was $2.0M, improved from $5.4M in Q3 2025. Cash fell to $0.2M. Nasdaq compliance regained.
